---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-018170"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2025-01-31T23:59:59+00:00"
generated_at: "2026-05-27T04:40:45.591979+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M

## Summary
- Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).
- PRIME study met both co-primary endpoints: 25% reduction in neonatal morbidity (NMI) and 18% reduction in neonatal length of stay in mITT population.
- ITT analysis: 20% reduction in NMI, 8% reduction in neonatal stay, and 20% reduction in NICU admissions.
- PreTRM test classified 23.5% as higher risk; number needed to screen 3-4 to save one NICU day.

## SEC filing metadata
- accession: 0001193125-25-018170
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2025-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000119312525018170/0001193125-25-018170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000119312525018170/d844948d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-018170
- JSON: https://secwatch.observer/filing/0001193125-25-018170.json
- Plain text: https://secwatch.observer/filing/0001193125-25-018170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.